BIOLOGIC/DISEASE-MODIFYING ANTIRHEUMATIC DRUG (DMARD)
Simponi is approved by the Food and Drug Administration (FDA) to treat adults with active cases of ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis (in combination with methotrexate), and moderate to severe ulcerative colitis in cases where when other treatments have failed or proven intolerable. Simponi is also referred to by its drug name, Golimumab.
Simponi is an immunomodulator, or in other words, a drug that modulates the immune system. Specifically, Simponi is considered a biologic disease-modifying antirheumatic drug (DMARD). Simponi is a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Simponi is believed to work by inhibiting tumor necrosis factor alpha (TNF-α), a chemical messenger involved in autoimmune attacks. read more
How do I take it?
Prescribing information states that Simponi is administered as a subcutaneous injection every four weeks after initial loading doses.
Simponi comes in a prefilled, single-dose autoinjector or syringe.
The FDA-approved label for Simponi lists common side effects including cold and flu symptoms and injection site reactions.
Rare but serious side effects listed for Simponi include severe infections, congestive heart failure, increased risk for lymphoma, demyelinating disorders such as multiple sclerosis, lupus-like syndrome, and hypersensitivity reactions.
For more details about this treatment, visit:
Simponi.com – Janssen